A case of rhabdomyolysis related to sorafenib treatment for advanced hepatocellular carcinoma
نویسندگان
چکیده
We report on a case of rhabdomyolysis related to sorafenib treatment for advanced hepatocellular carcinoma. A 70-year-old man was admitted to our hospital with fatigue, myalgia and an elevated creatine phosphokinase level. He was diagnosed as rhabdomyolysis related to sorafenib treatment for advanced hepatocellular carcinoma. After discontinuation of sorafenib, his fatigue and myalgia resolved and his creatine phosphokinase level returned to normal. Rhabdomyolysis related to sorafenib treatment is rare adverse effect. This is the first detailed case report of rhabdomyolysis related to sorafenib treatment.
منابع مشابه
The effect of nanomicelle curcumin, sorafenib, and combination of the two on the cyclin D1 gene expression of the hepatocellular carcinoma cell line (HUH7)
Objective(s): Hepatocellular carcinoma (HCC) is one of the most significant health condition around the world. As the only curative therapies, liver transplantation and surgical resection are the clinical treatments of HCC. Due to the systemic toxicity and severe side effects of these treatments, it is vital to establish new therapeutic approaches. The present study ai...
متن کاملA unique bleeding-related complication of sorafenib, a tyrosine kinase inhibitor, in advanced hepatocellular carcinoma: a case report
INTRODUCTION Sorafenib, a multikinase inhibitor as a standard of care for advanced hepatocellular carcinoma, may lead endothelial cells to an unstable state by blocking the signaling pathway of vascular endothelial growth factor receptor, which may result in the disruption of the architecture and integrity of the microvasculature, and eventually increase the risk of hemorrhage. Hemobilia is a r...
متن کاملLate-onset benefit in progressive advanced hepatocellular carcinoma with continued sorafenib therapy: a case report
INTRODUCTION In the past, no effective systemic therapy has existed for patients with advanced hepatocellular carcinoma. Sorafenib, an oral multikinase inhibitor, has recently been shown to improve overall survival in patients with advanced hepatocellular carcinoma in two randomized, double-blinded, placebo-controlled trials. This drug has been approved as the first-line therapy for advanced he...
متن کاملCASE REPORT Small intestinal perforation caused by metastatic tumor necrosis after sorafenib (Nexavar ) therapy for advanced hepatocellular carcinoma
Sorafenib (Nexavar , BAY 43-9006) is a novel multikinase inhibitor that has been recently approved for the treatment of advanced hepatocellular carcinoma (HCC). The increased use of sorafenib has been accompanied by an increase in the number of reports on the adverse effects of this drug. Generally, the adverse effects of sorafenib are well tolerated, and the most common drugrelated toxicities ...
متن کاملSorafenib in a patient with advanced hepatocellular carcinoma and serious impairment of left ventricular function: a case report
INTRODUCTION sorafenib, a tyrosine-kinase inhibitor, is widely used in the treatment of advanced hepatocellular carcinoma. Drug-related toxicities are generally mild but sorafenib, as other similar agents, may induce elevation of systemic arterial blood pressure levels in relation to an interaction with cardiovascular system probably mediated by HIF pathway. This side effect may be particularly...
متن کامل